Aveanna Healthcare (AVAH)


Market Price (9/10/2026): $14.04 | Market Cap: $3.1 BilSector: Health Care | Industry: Health Care Facilities

Aveanna Healthcare (AVAH)


Market Price (9/10/2026): $14.04
Market Cap: $3.1 Bil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.6%, FCF Yield is 5.2%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Chronic Disease Management, Show more.

Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%

Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 114%

Key risks
AVAH key risks include [1] margin pressure on its core Private Duty Services segment from persistent labor shortages and wage inflation and [2] significant interest rate exposure due to its substantial variable-rate debt.

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 4.6%, FCF Yield is 5.2%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Chronic Disease Management, Show more.
2 Trading close to highs
Dist 52W High is 0.0%, Dist 3Y High is 0.0%
3 Valuation getting more expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 114%
4 Key risks
AVAH key risks include [1] margin pressure on its core Private Duty Services segment from persistent labor shortages and wage inflation and [2] significant interest rate exposure due to its substantial variable-rate debt.

AVAH in ETFs

Weight = AVAH's share of each fund

VTI0.00%
ITOT0.00%
IWM0.03%
IHF0.17%
DFAS0.06%
IWO0.05%
SCHA0.03%
VTWO0.02%
+6 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 9/9/2026

Aveanna Healthcare (AVAH) stock has gained about 95% since 5/31/2026 because of the following key factors:

1. Aveanna Healthcare reported robust financial results for fiscal Q1 2026, which ended April 4, 2026, exceeding expectations and increasing its full-year guidance. Revenue for fiscal Q1 2026 increased by 15.9% year-over-year to $647.9 million, and adjusted EBITDA grew by 25.2% year-over-year to $84.4 million. Following this performance, the company raised its full-year 2026 revenue guidance to a range of $2.56 billion to $2.58 billion and its adjusted EBITDA guidance to between $328 million and $332 million.

2. The company announced strong fiscal Q2 2026 earnings, which ended June 2026, on August 13, 2026, significantly beating analyst consensus and further raising full-year guidance. Aveanna Healthcare reported an EPS of $0.22 for fiscal Q2 2026, surpassing the consensus estimate of $0.17 by $0.05. Quarterly revenue reached $670.48 million, exceeding the consensus estimate of $638.61 million by $31.87 million. This led to an updated full-year 2026 revenue guidance to "greater than $2.68 billion" and adjusted EBITDA guidance to "greater than $365 million."

Show more
Updated on 9/9/2026

Aveanna Healthcare (AVAH) stock has gained about 95% since 5/31/2026 because of the following key factors:

1. Aveanna Healthcare reported robust financial results for fiscal Q1 2026, which ended April 4, 2026, exceeding expectations and increasing its full-year guidance. Revenue for fiscal Q1 2026 increased by 15.9% year-over-year to $647.9 million, and adjusted EBITDA grew by 25.2% year-over-year to $84.4 million. Following this performance, the company raised its full-year 2026 revenue guidance to a range of $2.56 billion to $2.58 billion and its adjusted EBITDA guidance to between $328 million and $332 million.

2. The company announced strong fiscal Q2 2026 earnings, which ended June 2026, on August 13, 2026, significantly beating analyst consensus and further raising full-year guidance. Aveanna Healthcare reported an EPS of $0.22 for fiscal Q2 2026, surpassing the consensus estimate of $0.17 by $0.05. Quarterly revenue reached $670.48 million, exceeding the consensus estimate of $638.61 million by $31.87 million. This led to an updated full-year 2026 revenue guidance to "greater than $2.68 billion" and adjusted EBITDA guidance to "greater than $365 million."

3. Positive analyst sentiment, including multiple upgrades and increased price targets, fueled investor confidence. Following the strong Q2 2026 results, several firms raised their price targets for AVAH. BMO Capital Markets increased its target from $10.00 to $14.00, and Raymond James lifted its target from $13.00 to $15.00, both maintaining "Outperform" or "Strong Buy" ratings. RBC Capital also raised its price target from $10.00 to $16.00, influenced in part by an anticipated California private duty nursing rate increase for January 2027. The stock achieved a consensus rating of "Moderate Buy" with an average price target of $13.50.

4. Strategic growth initiatives, notably the acquisition of Family First Homecare and advancements in preferred payer relationships, contributed to the positive outlook. The pending acquisition of Family First Homecare, a Florida-based pediatric home care provider with approximately $120 million in revenue, was highlighted as a key driver for optimism and expected to add density in Florida. Furthermore, the company emphasized its "Preferred Payer and Government Affairs strategies," which underpin continued growth across all business segments. These efforts to expand market presence and improve reimbursement structures supported the company's strong performance.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 95.5% change in AVAH stock from 5/31/2026 to 9/9/2026 was primarily driven by a 88.9% change in the company's P/E Multiple.
(LTM values as of)53120269092026Change
Stock Price ($)7.1714.0295.5%
Change Contribution By: 
Total Revenues ($ Mil)2,5222,6033.2%
Net Income Margin (%)10.4%10.6%1.8%
P/E Multiple5.911.188.9%
Shares Outstanding (Mil)215218-1.5%
Cumulative Contribution95.5%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2026 to 9/9/2026
ReturnCorrelation
AVAH95.5% 
Market (SPY)0.8%9.0%
Sector (XLV)11.4%13.3%

Fundamental Drivers

The 90.5% change in AVAH stock from 2/28/2026 to 9/9/2026 was primarily driven by a 220.4% change in the company's Net Income Margin (%).
(LTM values as of)22820269092026Change
Stock Price ($)7.3614.0290.5%
Change Contribution By: 
Total Revenues ($ Mil)2,2912,60313.6%
Net Income Margin (%)3.3%10.6%220.4%
P/E Multiple20.411.1-45.5%
Shares Outstanding (Mil)209218-4.1%
Cumulative Contribution90.5%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 9/9/2026
ReturnCorrelation
AVAH90.5% 
Market (SPY)11.4%14.6%
Sector (XLV)4.4%19.6%

Fundamental Drivers

The 75.3% change in AVAH stock from 8/31/2025 to 9/9/2026 was primarily driven by a 1138.9% change in the company's Net Income Margin (%).
(LTM values as of)83120259092026Change
Stock Price ($)8.0014.0275.3%
Change Contribution By: 
Total Revenues ($ Mil)2,1782,60319.5%
Net Income Margin (%)0.9%10.6%1138.9%
P/E Multiple86.611.1-87.2%
Shares Outstanding (Mil)201218-7.7%
Cumulative Contribution75.2%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2025 to 9/9/2026
ReturnCorrelation
AVAH75.2% 
Market (SPY)19.2%19.7%
Sector (XLV)22.8%19.2%

Fundamental Drivers

The 873.6% change in AVAH stock from 8/31/2023 to 9/9/2026 was primarily driven by a 689.6% change in the company's P/S Multiple.
(LTM values as of)83120239092026Change
Stock Price ($)1.4414.02873.6%
Change Contribution By: 
Total Revenues ($ Mil)1,8332,60342.0%
P/S Multiple0.11.2689.6%
Shares Outstanding (Mil)189218-13.2%
Cumulative Contribution873.6%

LTM = Last Twelve Months as of date shown

Market Drivers

8/31/2023 to 9/9/2026
ReturnCorrelation
AVAH873.6% 
Market (SPY)75.3%28.6%
Sector (XLV)30.9%20.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
AVAH Return-36%-89%244%71%79%67%18%
Peers Return-5%-6%11%38%33%21%122%
S&P 500 Return27%-19%24%23%16%12%104%

Monthly Win Rates [3]
AVAH Win Rate33%17%50%58%58%78% 
Peers Win Rate40%50%54%67%62%67% 
S&P 500 Win Rate75%42%67%75%67%44% 

Max Drawdowns [4]
AVAH Max Drawdown--91%-41%-28%-38%-36% 
Peers Max Drawdown-43%-45%-27%-22%-28%-25% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, EHC, OPCH, BTSG, PNTG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/9/2026 (YTD)

How Low Can It Go

EventAVAHS&P 500
2025 US Tariff Shock
  % Loss-26.5%-18.8%
  % Gain to Breakeven36.1%23.1%
  Time to Breakeven3 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-39.1%-9.5%
  % Gain to Breakeven64.2%10.5%
  Time to Breakeven33 days24 days
2023 SVB Regional Banking Crisis
  % Loss-22.0%-6.7%
  % Gain to Breakeven28.2%7.1%
  Time to Breakeven7 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-83.9%-24.5%
  % Gain to Breakeven521.7%32.4%
  Time to Breakeven1043 days427 days

Compare to ADUS, EHC, OPCH, BTSG, PNTG

In The Past

Aveanna Healthcare's stock fell -26.5% during the 2025 US Tariff Shock. Such a loss loss requires a 36.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventAVAHS&P 500
2025 US Tariff Shock
  % Loss-26.5%-18.8%
  % Gain to Breakeven36.1%23.1%
  Time to Breakeven3 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-39.1%-9.5%
  % Gain to Breakeven64.2%10.5%
  Time to Breakeven33 days24 days
2023 SVB Regional Banking Crisis
  % Loss-22.0%-6.7%
  % Gain to Breakeven28.2%7.1%
  Time to Breakeven7 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-83.9%-24.5%
  % Gain to Breakeven521.7%32.4%
  Time to Breakeven1043 days427 days

Compare to ADUS, EHC, OPCH, BTSG, PNTG

In The Past

Aveanna Healthcare's stock fell -26.5% during the 2025 US Tariff Shock. Such a loss loss requires a 36.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Aveanna Healthcare (AVAH)

Aveanna Healthcare Holdings Inc. (AVAH) is a prominent diversified home care platform operating across the United States. The company's core mission is to enable patients, particularly those with complex medical needs, to receive high-quality care in the comfort of their homes. This approach minimizes the necessity and cost of traditional high-acuity settings such as hospitals and skilled nursing facilities, promoting better outcomes and quality of life for its patients.

AVAH's comprehensive services are delivered through three primary segments. The Private Duty Services (PDS) segment focuses on providing in-home skilled nursing for medically fragile children, including care in school settings, and offers pediatric therapy services like physical, occupational, and speech therapy. The Home Health & Hospice (HHH) segment delivers a range of in-home skilled nursing, therapy, and aide services for adult patients, alongside compassionate hospice care for individuals with life-limiting illnesses and their families. Lastly, the Medical Solutions (MS) segment supplies essential enteral nutrition products and other medical supplies directly to both adult and pediatric patients needing nutritional support.

AI Analysis | Feedback

Analogy 1: Amazon for comprehensive in-home medical care and supplies.

Analogy 2: Like a specialized DoorDash or Instacart for skilled nurses, therapists, and medical supplies delivered to your home.

AI Analysis | Feedback

  • Private Duty Nursing (PDN): Offers in-home skilled nursing and specialized care primarily for medically fragile children, including support in school settings and pediatric day healthcare centers.
  • Pediatric Therapy Services: Provides physical, occupational, and speech therapy services for children, delivered both in-clinic and within their homes.
  • Home Health Services: Delivers a range of in-home services for adults, including skilled nursing, physical, occupational, and speech therapy, as well as medical social and aide services.
  • Hospice Services: Offers compassionate care and support for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments.
  • Enteral Nutrition & Medical Supplies: Supplies specialized nutritional products and other medical items for home delivery to adults and children on a periodic or as-needed basis.

AI Analysis | Feedback

Aveanna Healthcare (AVAH) primarily sells its services and products directly to individuals and their families. Based on the company description, its major customer categories include:

  • Medically fragile children and their families: This category encompasses patients requiring private duty nursing (PDN) services, in-home skilled nursing, nursing services in school settings, pediatric day healthcare, and in-clinic or home-based pediatric therapy services (physical, occupational, and speech).
  • Adults requiring home health and hospice services: This includes individuals needing skilled nursing care, physical, occupational, and speech therapy services, medical social and aide services, and hospice care for life-limiting illnesses.
  • Individuals (children and adults) requiring enteral nutrition and other medical supplies: This category includes patients who receive enteral nutrition supplies and other related medical products delivered to their homes.

AI Analysis | Feedback

null

AI Analysis | Feedback

Jeff Shaner, President and Chief Executive Officer

Jeff Shaner was appointed President and Chief Executive Officer of Aveanna Healthcare in January 2023 and also serves on the Board of Directors. He was integral to the formation of Aveanna Healthcare in 2017 and brings over 20 years of experience in post-acute healthcare leadership. Mr. Shaner began his healthcare career in 2000 at Total Care, Inc., which was acquired by The Healthfield Group. He led the integration of multiple acquisitions at Healthfield, ultimately leading to its sale to Gentiva Health Services, Inc. in 2006. At Gentiva, he held various leadership positions, including President of the Hospice division, and led the integration of Odyssey Hospice, Inc. Following Gentiva's sale to Kindred Healthcare in 2015, he provided consulting services to private equity firms Linden Capital Partners and Blue Wolf Capital, and also served as an operating partner for these firms. He then joined PSA Healthcare as Chief Operating Officer in 2015, which was instrumental in the creation of Aveanna Healthcare.

Matt Buckhalter, Chief Financial Officer

Matt Buckhalter was appointed Chief Financial Officer of Aveanna Healthcare, effective January 1, 2024, after serving as interim CFO since July 2023. He joined Aveanna in 2016 and has been responsible for corporate and operational finance, business intelligence, financial planning and analysis, and investor relations. Previously, Mr. Buckhalter held the role of Senior Vice President of Finance, leading the company's Investor Relations Group. Before joining Aveanna, he was Vice President of Finance for RT Capital and served as a senior financial analyst for Gentiva Health Services.

Rodney Windley, Chairman of the Board

Rodney Windley serves as Chairman of the Board of Aveanna Healthcare and has a long and distinguished career spanning over 40 years in the healthcare industry. He co-founded Central Health Services in the 1980s, which was later sold to Columbia HCA. In 1989, he founded The Healthfield Group, serving as its Chairman and Chief Executive Officer until its merger with Gentiva Health Services in 2009. He then served as Vice Chairman and later Executive Chairman of Gentiva, guiding it through its merger with Kindred Healthcare in 2015. Prior to the formation of Aveanna in 2017, Mr. Windley was the Executive Chairman of PSA Healthcare. He is recognized as one of the executive founders of Aveanna Healthcare, which was formed through the combination of Epic Health Services and PSA Healthcare, backed by private equity sponsors Bain Capital and J.H. Whitney.

Jerry Perchik, Chief Legal Officer and Secretary

Jerry Perchik serves as Aveanna's Chief Legal Officer and Secretary, acting as the primary legal advisor to the CEO, senior management team, and Board of Directors. He brings over fifteen years of experience in corporate law and the healthcare industry, having previously served as Chief Legal Officer for MedQuest Associates. Mr. Perchik has held various corporate leadership and legal roles in both publicly traded and private equity-sponsored healthcare companies.

Ed Reisz, Chief Administrative Officer

Ed Reisz is the Chief Administrative Officer of Aveanna Healthcare, with over 30 years of successful experience in the Home Care industry. Before the formation of Aveanna Healthcare, Mr. Reisz held the position of Executive Vice President and Chief Human Resource Officer for PSA Healthcare. Prior to joining PSA, he was Senior Vice President and Chief Human Resource Officer for Gentiva Health Services.

AI Analysis | Feedback

The key risks to Aveanna Healthcare (AVAH) primarily revolve around its reliance on government payers, the challenging labor market for healthcare professionals, and its substantial debt load.

  1. Labor Shortages and Wage Inflation: Aveanna Healthcare faces a persistent industry-wide challenge of workforce shortages, particularly for skilled nurses and therapists, which affects its ability to expand caregiver capacity. This scarcity of clinical staff leads to increased wage inflation, driving up operating costs and putting pressure on the company's margins, especially in its Private Duty Services segment. The competitive labor market, with increased competition from hospitals and travel agencies, makes it difficult to recruit and retain qualified personnel, despite the strong demand for home- and community-based care.

  2. Reimbursement Rate Pressures and Regulatory Changes: A significant portion of Aveanna's revenue, estimated between 75% and 90%, is derived from government payers such as Medicaid and Medicare. Consequently, the company is highly susceptible to unpredictable changes in Medicare/Medicaid reimbursement rates and payment methodologies, as well as broader healthcare reform and other regulations. While Aveanna actively pursues and has secured rate increases in various states, especially through its preferred payer strategy, the ongoing political risk tied to government reimbursement and state budget cycles remains a primary financial lever that can impact its profitability and revenue growth.

  3. High Indebtedness and Interest Rate Risk: Aveanna Healthcare operates with substantial financial leverage, having approximately $1.49 billion in variable-rate debt as of late 2025. This high level of indebtedness makes the company vulnerable to general adverse economic conditions and limits its flexibility to pursue strategic alternatives. A "higher-for-longer" interest rate environment, characterized by elevated Secured Overnight Financing Rate (SOFR) levels, directly impacts Aveanna's cost of capital and increases its interest expense. Previous assessments have noted the company's "very high financial leverage" and potential risk of default.

AI Analysis | Feedback

The following clear emerging threats have been identified for Aveanna Healthcare (AVAH):

  • Disruptive E-commerce and Direct-to-Consumer Medical Supply Platforms: Aveanna's Medical Solutions segment, which provides enteral nutrition supplies and other products, faces an emerging threat from large-scale e-commerce giants and specialized online retailers. These platforms can leverage superior logistics, broader product offerings, and potentially lower overhead to deliver medical supplies more efficiently and at competitive prices directly to consumers. This ongoing shift in retail, expanding into the medical supply sector, poses a direct challenge to Aveanna's distribution model by offering increased convenience and potentially lower costs, akin to the Netflix disruption of Blockbuster.
  • Technology-Enabled Direct Caregiver-to-Patient Platforms: For Aveanna's Private Duty Services (PDS) and Home Health & Hospice (HHH) segments, particularly for personal care services, medical social services, aide services, and less complex therapy, there is an emerging threat from technology-driven platforms that directly connect patients/families with qualified independent caregivers and therapists. These "Uber-like" models aim to disintermediate traditional home care agencies by offering greater flexibility, transparent pricing, and potentially lower costs through reduced overhead. While the highly specialized and regulated nature of care for medically fragile children creates a barrier for these platforms in Aveanna's core PDN services, their expansion into broader home health and personal care markets could siphon off business from Aveanna's diversified offerings.

AI Analysis | Feedback

Aveanna Healthcare (AVAH) operates in several significant addressable markets within the United States for its main products and services:

  • Private Duty Nursing (PDN) Services: The U.S. private nursing services market generated a revenue of USD 1,844.1 million in 2023. This market is projected to reach USD 2,693.6 million by 2030, exhibiting a compound annual growth rate (CAGR) of 5.6% from 2024 to 2030.
  • Adult Home Health Services: The U.S. home healthcare services market size was valued at USD 100.95 billion in 2024. It is projected to grow from USD 107.07 billion in 2025 to USD 176.30 billion by 2032, with a CAGR of 7.4% during the forecast period.
  • Hospice Services: The U.S. hospice market was estimated at USD 29.92 billion in 2024. This market is projected to grow at a CAGR of 4.61% from 2025 to 2030, reaching an estimated USD 39.09 billion by 2030.
  • Home-based Pediatric Therapy Services: The U.S. pediatric home healthcare market was valued at USD 20.1 billion in 2024. The market is anticipated to grow from USD 21.4 billion in 2025 to USD 38.9 billion in 2034, growing at a CAGR of 6.9% from 2025 to 2034.
  • Enteral Nutrition Services: The U.S. enteral nutrition products market size was valued at USD 2.84 billion in 2023. The market is projected to grow from USD 2.98 billion in 2024 to USD 4.86 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period.

AI Analysis | Feedback

Aveanna Healthcare Holdings Inc. (AVAH) is expected to drive future revenue growth over the next two to three years through several key strategies:

  1. Expansion and Organic Growth in Home Health & Hospice Services: Aveanna Healthcare anticipates its Home Health & Hospice segment to be a significant growth engine, projecting an organic growth rate of 5% to 7% for 2026. This growth is expected to be fueled by increased patient admissions and a focus on episodic care.
  2. Strategic Acquisitions (Tuck-in M&A): The company is actively pursuing smaller, "tuck-in" acquisitions across its Private Duty Services, Home Health & Hospice, and Medical Solutions segments. Aveanna aims for approximately 3% annual growth from these strategic acquisitions, exemplified by its June 2025 acquisition of Thrive Skilled Pediatric Care.
  3. Optimization of Payer Relationships and Reimbursement Rates: Aveanna is implementing "preferred payer and government affairs strategies" to strengthen relationships with payers and government entities. These efforts are designed to secure more favorable reimbursement rates and value-based agreements, which have already contributed to increased revenue in its home health and hospice divisions.
  4. Increased Patient Volume and Enhanced Rates in Private Duty Services: The Private Duty Services (PDS) segment is a crucial revenue driver, with growth stemming from increased patient volumes and improved reimbursement rates. The company is focused on aligning its clinical capacity and recruitment efforts with preferred payer partners to achieve accelerated organic growth in this segment.
  5. Modernization of Medical Solutions and Introduction of New Offerings: Aveanna is dedicated to modernizing its Medical Solutions services and introducing new offerings to generate high-margin revenue streams. A notable initiative is the launch of a proprietary enteral nutrition supply division, which aims to capture more of the total cost of care for its medically complex patient population.

AI Analysis | Feedback

Share Issuance

  • Aveanna Healthcare completed its Initial Public Offering (IPO) on April 29, 2021, offering 38,236,000 shares of common stock at $12.00 per share. Underwriters were granted an option to purchase up to an additional 5,735,400 shares.
  • In October 2025, selling stockholders associated with J.H. Whitney Equity Partners VII conducted a secondary offering of 10,000,000 shares of common stock at $9.00 per share. Aveanna Healthcare did not sell any shares or receive proceeds from this offering.

Outbound Investments

  • In April 2025, Aveanna announced the acquisition of Thrive Skilled Pediatric Care for $75 million, funded by a combination of common stock and cash. This acquisition was completed in June 2025.
  • In 2021, the company acquired Comfort Care, an adult home health and hospice company, for $345 million.
  • Also in 2021, Aveanna acquired Accredited Home Care, a private duty services company, for a base purchase price of $180 million.

Capital Expenditures

  • Aveanna Healthcare's capital expenditures in the last 12 months were approximately -$7.03 million.
  • In Q3 2022, capital expenditures amounted to $2.8 million, primarily used to fund long-term assets and infrastructure.
  • The company is focused on investments in clinical innovation, data and analytics, recruitment, and technology to support efficient growth, and is upgrading its digital systems for scheduling, billing, and care coordination.

Better Bets vs. Aveanna Healthcare (AVAH)

Peer Outperformance in Health Care Facilities

AVAH has outperformed 74% of its 23 Health Care Facilities peers over 5Y. Among the peers that beat it is NHC. Health Care Facilities ranks 4th of 10 industries in Health Care by median 5Y return.
Share of Health Care Facilities constituents that AVAH has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
83%
of 30 industry peers · 69.7% return
3Y
100%
of 25 industry peers · 908.6% return
5Y
74%
of 23 industry peers · 56.5% return
Health Care Facilities peers with revenue growth within 4pp of AVAH's that beat it on at least 2 of 3 windows, and by at least 20pp over 5Y. Growth is matched by construction, so the gap is largely a re-rating gap. The multiple column is the context for it.
Ticker Name Rev Growth 3Y Avg P/E 1Y3Y5Y 5Y Gap
AVAH Aveanna Healthcare 12.5% 11.1x 69.7%908.6%56.5%
NHC National Healthcare 13.0% 25.3x 102.7%260.9%270.7% +214pp
Price returns, excluding dividends. P/E shown for context only and not used for matching.
Median price return by industry across the Health Care sector, ranked by 5Y. Health Care Facilities is AVAH's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 7 9.1%83.8%83.8% CAH 407% · MCK 351% · COR 178%
Managed Health Care 8 38.3%-4.9%6.6% OSCR 81% · HQY 45% · ELV 18%
Health Care Services 20 17.3%51.9%0.9% HIMS 220% · RDNT 141% · DGX 67%
Health Care Facilities ← 24 1.4%4.2%-16.7% NHC 271% · THC 270% · ENSG 117%
Health Care Equipment 50 -3.5%-2.1%-26.1% POCI 10775% · UFPT 319% · GKOS 243%
Health Care Supplies 12 25.1%-12.6%-36.3% LNTH 288% · HAE 53% · MMSI 22%
Pharmaceuticals 62 -3.0%4.7%-38.5% LQDA 2441% · INDV 1146% · ETON 1074%
Life Sciences Tools & Services 109 -2.3%-26.5%-71.5% SNWV 1549% · MEDP 206% · AXGN 188%
Health Care Technology 20 -25.4%-55.7%-78.6% SPOK 76% · HSTM -3% · VEEV -14%
Biotechnology 362 -0.2%-25.2%-78.7% DNTH 1575% · CELZ 1386% · ELVN 1206%
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

AVAHADUSEHCOPCHBTSGPNTGMedian
NameAveanna .Addus Ho.Encompas.Option C.BrightSp.Pennant  
Mkt Price14.02119.23121.5223.6461.9939.6050.80
Mkt Cap3.12.212.03.612.81.43.3
Rev LTM2,6031,4766,2065,69414,3721,1024,148
Op Inc LTM2821481,11733444862308
FCF LTM15815541330440235231
FCF 3Y Avg8211635624720529160
CFO LTM1681621,21234750653258
CFO 3Y Avg901241,06328829241206

Growth & Margins

AVAHADUSEHCOPCHBTSGPNTGMedian
NameAveanna .Addus Ho.Encompas.Option C.BrightSp.Pennant  
Rev Chg LTM19.5%15.9%9.5%5.9%26.4%37.9%17.7%
Rev Chg 3Y Avg12.5%13.9%10.7%11.4%21.9%30.1%13.2%
Rev Chg Q13.7%8.0%9.6%1.9%23.0%35.8%11.7%
QoQ Delta Rev Chg LTM3.2%1.9%2.3%0.5%5.3%7.7%2.8%
Op Inc Chg LTM30.1%27.5%15.5%-0.1%143.5%44.0%28.8%
Op Inc Chg 3Y Avg69.4%23.8%17.4%6.4%164.0%36.9%30.3%
Op Mgn LTM10.8%10.0%18.0%5.9%3.1%5.7%8.0%
Op Mgn 3Y Avg8.9%9.4%16.9%6.3%1.4%5.4%7.6%
QoQ Delta Op Mgn LTM-0.3%0.2%0.1%0.0%0.4%0.2%0.1%
CFO/Rev LTM6.5%11.0%19.5%6.1%3.5%4.8%6.3%
CFO/Rev 3Y Avg3.7%9.6%18.7%5.5%2.4%4.9%5.2%
FCF/Rev LTM6.1%10.5%6.7%5.3%2.8%3.1%5.7%
FCF/Rev 3Y Avg3.4%8.9%6.2%4.7%1.6%3.5%4.1%

Valuation

AVAHADUSEHCOPCHBTSGPNTGMedian
NameAveanna .Addus Ho.Encompas.Option C.BrightSp.Pennant  
Mkt Cap3.12.212.03.612.81.43.3
P/S1.21.51.90.60.91.31.2
P/Op Inc10.814.710.710.828.522.212.8
P/EBIT11.014.510.410.628.521.812.8
P/E11.120.719.317.334.942.720.0
P/CFO18.213.49.910.425.225.915.8
Total Yield9.0%4.8%5.8%5.8%2.9%2.3%5.3%
Dividend Yield0.0%0.0%0.6%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg6.0%6.1%3.4%6.0%2.6%2.9%4.7%
D/E0.50.00.20.40.20.40.3
Net D/E0.50.00.20.30.10.30.3

Returns

AVAHADUSEHCOPCHBTSGPNTGMedian
NameAveanna .Addus Ho.Encompas.Option C.BrightSp.Pennant  
1M Rtn48.2%-0.1%-3.4%-3.5%0.9%-0.1%-0.1%
3M Rtn103.5%28.0%17.8%10.6%2.3%22.6%20.2%
6M Rtn99.4%15.7%21.2%-20.6%50.0%16.4%18.8%
12M Rtn69.7%5.5%-2.3%-19.2%136.2%59.5%32.5%
3Y Rtn908.6%41.3%78.2%-31.1%463.5%242.0%160.1%
1M Excs Rtn49.7%1.4%-1.9%-2.0%2.4%1.4%1.4%
3M Excs Rtn100.7%25.2%13.5%8.6%-1.8%17.5%15.5%
6M Excs Rtn81.8%4.1%1.5%-32.8%37.3%3.7%3.9%
12M Excs Rtn52.2%-13.3%-20.4%-37.7%125.7%44.0%15.3%
3Y Excs Rtn811.3%-31.9%5.9%-100.7%394.4%159.8%82.8%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil2026202420232022
Private Duty Services (PDS)2,0011,6351,5191,358
Home Health and Hospice (HHH)249218219177
Medical Solutions (MS)183172158143
Total2,4332,0251,8951,679


Price Behavior

Price Behavior
Market Price$14.02 
Market Cap ($ Bil)3.1 
First Trading Date04/29/2021 
Distance from 52W High0.0% 
   50 Days200 Days
DMA Price$10.72$8.43
DMA Trendupup
Distance from DMA30.7%66.4%
 3M1YR
Volatility62.5%50.6%
Downside Capture-128.6251.19
Upside Capture231.18102.99
Correlation (SPY)13.3%20.6%
AVAH Betas & Captures as of 8/31/2026

 1M2M3M6M1Y3Y
Beta1.641.270.350.590.761.39
Up Beta-0.74-0.820.290.641.021.25
Down Beta2.082.180.660.270.561.45
Up Capture551%373%180%131%99%854%
Bmk +ve Days10213268138427
Stock +ve Days12223868128355
Down Capture-134%-3%-176%-1%58%104%
Bmk -ve Days11213259113324
Stock -ve Days9192457118366

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with AVAH
AVAH70.1%50.5%1.21-
Sector ETF (XLV)22.5%16.2%1.0619.4%
Equity (SPY)18.6%12.8%1.0620.2%
Gold (GLD)20.6%29.2%0.648.1%
Commodities (DBC)46.3%20.4%1.76-13.9%
Real Estate (VNQ)7.3%13.6%0.2724.4%
Bitcoin (BTCUSD)-29.8%43.8%-0.6813.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with AVAH
AVAH9.0%79.0%0.44-
Sector ETF (XLV)5.9%15.2%0.2021.4%
Equity (SPY)12.5%17.2%0.5526.6%
Gold (GLD)18.9%18.8%0.827.0%
Commodities (DBC)11.1%19.5%0.442.2%
Real Estate (VNQ)1.2%18.9%-0.0425.8%
Bitcoin (BTCUSD)10.8%52.6%0.3921.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with AVAH
AVAH2.3%76.9%0.38-
Sector ETF (XLV)10.4%16.7%0.5021.0%
Equity (SPY)15.1%17.9%0.7226.5%
Gold (GLD)12.3%16.3%0.627.1%
Commodities (DBC)8.1%18.1%0.372.8%
Real Estate (VNQ)4.7%20.7%0.1925.8%
Bitcoin (BTCUSD)63.6%66.2%1.0319.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date8142026
Short Interest: Shares Quantity5.3 Mil
Short Interest: % Change Since 731202621.0%
Average Daily Volume3.3 Mil
Days-to-Cover Short Interest1.6 days
Basic Shares Quantity217.8 Mil
Short % of Basic Shares2.5%

Earnings Returns History

Updated 8/24/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/13/202624.8%45.4% 
5/14/20269.9%13.4%4.7%
3/19/2026-8.2%-4.2%-2.0%
1/14/202610.0%5.9%-7.8%
11/6/2025-6.3%-4.5%-0.1%
8/7/202549.4%83.8%111.3%
5/8/202514.1%20.7%14.3%
3/13/202537.4%47.3%28.3%
...
SUMMARY STATS   
# Positive141411
# Negative779
Median Positive10.0%17.8%14.3%
Median Negative-6.7%-5.6%-6.4%
Max Positive49.4%83.8%111.3%
Max Negative-9.0%-33.2%-27.7%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/13/202624.8%45.4% 
5/14/20269.9%13.4%4.7%
3/19/2026-8.2%-4.2%-2.0%
1/14/202610.0%5.9%-7.8%
11/6/2025-6.3%-4.5%-0.1%
8/7/202549.4%83.8%111.3%
5/8/202514.1%20.7%14.3%
3/13/202537.4%47.3%28.3%
11/7/202416.2%19.3%11.4%
8/8/202432.2%33.5%58.0%
5/9/20242.5%12.4%2.9%
3/14/2024-3.0%-2.4%-6.4%
11/9/20232.0%27.9%75.8%
5/11/20233.8%16.2%26.7%
3/16/2023-6.7%-33.2%-16.1%
11/9/2022-9.0%-24.3%-27.7%
8/11/20220.9%0.5%-3.3%
5/11/2022-5.8%5.4%11.2%
11/15/2021-7.6%-12.6%-23.6%
8/11/20215.9%-5.6%-5.1%
5/25/20211.7%4.4%12.5%
SUMMARY STATS   
# Positive141411
# Negative779
Median Positive10.0%17.8%14.3%
Median Negative-6.7%-5.6%-6.4%
Max Positive49.4%83.8%111.3%
Max Negative-9.0%-33.2%-27.7%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202503/19/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202403/13/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/09/202410-Q
12/31/202303/14/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/16/202310-K
09/30/202211/15/202210-Q
Collapse to Preview
Report DateFiling DateFiling
06/30/202608/13/202610-Q
03/31/202605/14/202610-Q
12/31/202503/19/202610-K
09/30/202511/06/202510-Q
06/30/202508/07/202510-Q
03/31/202505/08/202510-Q
12/31/202403/13/202510-K
09/30/202411/07/202410-Q
06/30/202408/08/202410-Q
03/31/202405/09/202410-Q
12/31/202303/14/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/16/202310-K
09/30/202211/15/202210-Q
06/30/202208/11/202210-Q
03/31/202205/11/202210-Q
12/31/202103/28/202210-K
09/30/202111/15/202110-Q
06/30/202108/11/202110-Q
03/31/202105/25/202110-Q
12/31/202004/30/2021424B4

Recent Forward Guidance

Updated 8/14/2026

Latest: Q2 2026 Earnings Reported 8/13/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported 2.68 Bil   RaisedGuidance: 2.57 Bil for 2026
2026 Adjusted EBITDAReported 365.00 Mil   RaisedGuidance: 330.00 Mil for 2026


Prior: Q1 2026 Earnings Reported 5/14/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported2.56 Bil2.57 Bil2.58 Bil0.8% RaisedGuidance: 2.55 Bil for 2026
2026 Adjusted EBITDAReported328.00 Mil330.00 Mil332.00 Mil3.1% RaisedGuidance: 320.00 Mil for 2026

Q4 2025 Earnings Reported 3/19/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 RevenueReported2.54 Bil2.55 Bil2.56 Bil0 AffirmedGuidance: 2.55 Bil for 2026
2026 Adjusted EBITDAReported318.00 Mil320.00 Mil322.00 Mil0 AffirmedGuidance: 320.00 Mil for 2026

Q4 2025 Earnings Reported 1/14/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2025 RevenueReported2.42 Bil2.44 Bil2.44 Bil2.5% RaisedGuidance: 2.38 Bil for 2025
2025 Adjusted EBITDAReported318.00 Mil320.00 Mil322.00 Mil6.7% RaisedGuidance: 300.00 Mil for 2025
2025 Normalized Adjusted EBITDAReported298.00 Mil300.00 Mil302.00 Mil   
2025 Net IncomeReported181.00 Mil200.50 Mil220.00 Mil   
2026 RevenueReported2.54 Bil2.55 Bil2.56 Bil   
2026 Adjusted EBITDAReported318.00 Mil320.00 Mil322.00 Mil   

Insider Activity

Updated 8/24/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1J.h., Whitney Equity Partners Vii, Llc PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
2Williams, Robert M JR PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
3Vigano, Paul R PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
4J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell824202611.5010,112,125  Form
5J.h., Whitney Equity Partners Vii, Llc PSA Healthcare Investment Holding LLCSell824202611.50957,91811,016,057167,507,758Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1J.h., Whitney Equity Partners Vii, Llc PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
2Williams, Robert M JR PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
3Vigano, Paul R PSA Healthcare Investment Holding LLCSell824202611.502,250,00025,875,000141,632,758Form
4J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell824202611.5010,112,125  Form
5J.h., Whitney Equity Partners Vii, Llc PSA Healthcare Investment Holding LLCSell824202611.50957,91811,016,057167,507,758Form
6J.h., Whitney Equity Partners Vii, Llc PSA Iliad Holdings LLCSell824202611.501,426,034  Form
7Williams, Robert M JR J.H. Whitney VII, L.P.Sell824202611.5010,112,125  Form
8Williams, Robert M JR PSA Healthcare Investment Holding LLCSell824202611.50957,91811,016,057167,507,758Form
9Williams, Robert M JR JHW Iliad Holdings, LLCSell824202611.501,813,795  Form
10Williams, Robert M JR PSA Iliad Holdings LLCSell824202611.501,426,034  Form
11Williams, Robert M JR JHW Iliad Holdings II, LLCSell824202611.50190,130  Form
12Vigano, Paul R J.H. Whitney VII, L.P.Sell824202611.5010,112,125  Form
13Vigano, Paul R PSA Healthcare Investment Holding LLCSell824202611.50957,91811,016,057167,507,758Form
14Vigano, Paul R JHW Iliad Holdings, LLCSell824202611.501,813,795  Form
15Vigano, Paul R PSA Iliad Holdings LLCSell824202611.501,426,034  Form
16Vigano, Paul R JHW Iliad Holdings II, LLCSell824202611.50190,130  Form
17Windley, Rodney D DirectSell824202611.50180,0002,070,00023,897,196Form
18Shaner, JeffChief Executive OfficerDirectSell824202611.5090,0001,035,00029,462,678Form
19Reisz, Edwin CChief Administrative OfficerDirectSell824202611.5050,000575,00016,075,816Form
20Williams, Robert M JR J.H. Whitney VII, L.P.Sell70220268.012,419,03519,376,47080,998,105Form
21Williams, Robert M JR JHW Iliad Holdings LLCSell70220268.01525,8444,212,01014,528,498Form
22Williams, Robert M JR JHW Iliad Holdings II LLCSell70220268.0155,121441,5191,522,941Form
23Vigano, Paul R J.H. Whitney VII, L.P.Sell70220268.012,419,03519,376,47080,998,105Form
24Vigano, Paul R JHW Iliad Holdings LLCSell70220268.01525,8444,212,01014,528,498Form
25Vigano, Paul R JHW Iliad Holdings II LLCSell70220268.0155,121441,5191,522,941Form
26J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell70220268.012,419,03519,376,47080,998,105Form
27Williams, Robert M JR J.H. Whitney VII, L.P.Sell62620268.00919,3897,355,112100,249,264Form
28Williams, Robert M JR JHW Iliad Holdings LLCSell62620268.0072,963583,70418,717,112Form
29Williams, Robert M JR JHW Iliad Holdings II LLCSell62620268.007,64861,1841,962,008Form
30J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell62620268.00919,3897,355,112100,249,264Form
31Vigano, Paul R J.H. Whitney VII, L.P.Sell62620268.00919,3897,355,112100,249,264Form
32Vigano, Paul R JHW Iliad Holdings LLCSell62620268.0072,963583,70418,717,112Form
33Vigano, Paul R JHW Iliad Holdings II LLCSell62620268.007,64861,1841,962,008Form
34Vigano, Paul R J.H. Whitney VII, L.P.Sell60520266.245,842,24036,455,57883,931,413Form
35Vigano, Paul R JHW Iliad Holdings LLCSell60520266.241,047,9136,538,97715,054,636Form
36Vigano, Paul R JHW Iliad Holdings II LLCSell60520266.24109,847685,4451,578,090Form
37Williams, Robert M JR J.H. Whitney VII, L.P.Sell60520266.245,842,24036,455,57883,931,413Form
38Williams, Robert M JR JHW Iliad Holdings LLCSell60520266.241,047,9136,538,97715,054,636Form
39Williams, Robert M JR JHW Iliad Holdings II LLCSell60520266.24109,847685,4451,578,090Form
40J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell60520266.245,842,24036,455,57883,931,413Form
41Cunningham, Patrick AChief Compliance OfficerDirectSell52120267.59125,000948,5381,614,449Form
42Shaner, JeffChief Executive OfficerDirectSell21920267.21173,2251,248,64019,108,160Form
43Cunningham, Patrick AChief Compliance OfficerDirectSell21920267.2118,436132,8902,434,606Form
44Buckhalter, MatthewChief Financial OfficerDirectSell21920267.2113,51297,3973,814,889Form
45Stewart, DeborahSVP, Chief Accounting OfficerDirectSell21920267.2111,18180,5952,175,485Form
46Reisz, Edwin CChief Administrative OfficerDirectSell21920267.2160,769438,03510,430,676Form
47Shaner, JeffChief Executive OfficerDirectSell21920267.38168,8001,246,23420,850,173Form
48Cunningham, Patrick AChief Compliance OfficerDirectSell21920267.3817,965132,6342,629,723Form
49Buckhalter, MatthewChief Financial OfficerDirectSell21920267.3813,16797,2114,007,106Form
50Stewart, DeborahSVP, Chief Accounting OfficerDirectSell21920267.3810,89680,4442,310,759Form
51Reisz, Edwin CChief Administrative OfficerDirectSell21920267.3859,217437,19311,132,129Form
52Shaner, JeffChief Executive OfficerDirectSell21920267.65119,884916,52522,881,150Form
53Cunningham, Patrick AChief Compliance OfficerDirectSell21920267.6512,75997,5442,860,460Form
54Buckhalter, MatthewChief Financial OfficerDirectSell21920267.659,35171,4894,250,079Form
55Stewart, DeborahSVP, Chief Accounting OfficerDirectSell21920267.657,73859,1582,476,126Form
56Reisz, Edwin CChief Administrative OfficerDirectSell21920267.6542,057321,53011,980,200Form
57Cunningham, Patrick AChief Compliance OfficerDirectSell10220267.8512,44597,6342,301,421Form
58Reisz, Edwin CChief Administrative OfficerDirectSell10220267.8517,613138,17810,364,404Form
59Shaner, JeffChief Executive OfficerDirectSell10220267.8529,357230,31218,782,813Form
60Stewart, DeborahSVP, Chief Accounting OfficerDirectSell10220267.8511,96293,8441,974,449Form
61Buckhalter, MatthewChief Financial OfficerDirectSell10220267.8518,340143,8813,428,195Form
62Cunningham, Patrick AChief Compliance OfficerDirectSell10220268.1811,73195,9332,500,732Form
63Reisz, Edwin CChief Administrative OfficerDirectSell10220268.1816,602135,76610,947,708Form
64Shaner, JeffChief Executive OfficerDirectSell10220268.1827,674226,31019,818,950Form
65Stewart, DeborahSVP, Chief Accounting OfficerDirectSell10220268.1811,27592,2042,155,952Form
66Buckhalter, MatthewChief Financial OfficerDirectSell10220268.1817,289141,3843,723,470Form
67Cunningham, Patrick AChief Compliance OfficerDirectSell10220268.3611,83998,9222,653,154Form
68Reisz, Edwin CChief Administrative OfficerDirectSell10220268.3616,755139,99811,324,587Form
69Shaner, JeffChief Executive OfficerDirectSell10220268.3627,929233,36420,481,330Form
70Stewart, DeborahSVP, Chief Accounting OfficerDirectSell10220268.3611,37995,0782,297,063Form
71Buckhalter, MatthewChief Financial OfficerDirectSell10220268.3617,448145,7893,948,932Form
72Vigano, Paul R J.H. Whitney VII, L.P.Sell102820259.001,251,90911,267,181173,635,083Form
73Vigano, Paul R JHW Iliad Holdings LLCSell102820259.00224,5532,020,97731,144,635Form
74Vigano, Paul R JHW Iliad Holdings II LLCSell102820259.0023,538211,8423,264,714Form
75J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell102820259.001,251,90911,267,181173,635,083Form
76Williams, Robert M JR J.H. Whitney VII, L.P.Sell102820259.001,251,90911,267,181173,635,083Form
77Williams, Robert M JR JHW Iliad Holdings LLCSell102820259.00224,5532,020,97731,144,635Form
78Williams, Robert M JR JHW Iliad Holdings II LLCSell102820259.0023,538211,8423,264,714Form
79Williams, Robert M JR J.H. Whitney VII, L.P.Sell102320259.008,346,05975,114,531184,902,264Form
80Williams, Robert M JR JHW Iliad Holdings LLCSell102320259.001,497,01813,473,16233,165,612Form
81Williams, Robert M JR JHW Iliad Holdings II LLCSell102320259.00156,9231,412,3073,476,556Form
82Vigano, Paul R J.H. Whitney VII, L.P.Sell102320259.008,346,05975,114,531184,902,264Form
83Vigano, Paul R JHW Iliad Holdings LLCSell102320259.001,497,01813,473,16233,165,612Form
84Vigano, Paul R JHW Iliad Holdings II LLCSell102320259.00156,9231,412,3073,476,556Form
85J.h., Whitney Equity Partners Vii, Llc J.H. Whitney VII, L.P.Sell102320259.008,346,05975,114,531184,902,264Form

Investor Activity (13F)

Updated Sep 10, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Summit Partners L P$35.1 Mil5.2%7TRIM -27.8%13F
Active Manager
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Summit Partners L P$35.1 Mil5.2%7TRIM -27.8%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Summit Partners L P$35.1 Mil5.2%7TRIM -27.8%13F
Core Cache Last Updated: 9/9/2026